Synovetin OA™ transforms the treatment of canine osteoarthritis1
Improves mobility so dogs can be life-loving pets again
Just 1 minimally-invasive injection relieves pain and inflammation for up to 1 year2
Synovetin OA™—Targets Synovial Inflammation1
Restores active lifestyle
Provides durable pain and inflammation relief
Alters the treatment of chronic OA
Effectiveness was demonstrated in a multi-center study2
Sites included Gulf Coast Veterinary Specialists, Louisiana State University School of Veterinary Medicine, and University of Missouri College of Veterinary Medicine.
3 validation metrics confirm formidable and durable treatment effect:
- Effectiveness evaluated in Grade 1 & 2 and Grade 3 elbow OA
- Dogs were given a single injection in 1 or 2 elbows and followed for 12 months
- Study population included 69 dogs and 92 elbows
Images of synovitis and administration of Synovetin OA™ are courtesy of Dr. Caleb Hudson, DVM, DACVS and Dr. Michelle Fabiani, DVM DACVR, Gulf Coast Veterinary Specialists
Synovetin OA™ utilizes the procedure of Radio-Synovi-Orthesis (RSO) to break the cycle of inflammation and pain1
RSO is a well-established human procedure that has been successfully used for over 60 years3,4
The active agent of Synovetin OA™ is Tin-117m, a unique conversion electron therapeutic veterinary device in an injectable colloidal suspension.1
Microparticles of Synovetin OA™ selectively target the source of inflammatory mediators through dual cellular targeting (macrophages, activated synoviocytes)2,5
RSO in people3,4
Patients who have had RSO:
More than 670,000
Joints injected using RSO:
More than 830,000
40,000 to 50,000
procedures in Germany annually
View the dual cellular targeting
of Synovetin OA™ in action.
Synovetin OA™ redefines conservative management of chronic OA— transforming the treatment approach with 1 minimally-invasive procedure that provides safety and long-term efficacy.2
Overall Treatment Success2*
Dogs with Grade 1 & 2 Elbow OA—
92%†
†1 elbow treated; n=12/13
Dogs with Grade 3 Elbow OA—
71.4%‡
‡Both elbows treated; n=10/14
*Overall treatment success based on a composite of force plate, Canine Brief Pain Inventory (CBPI), and clinician lameness assessments for the label dose.
Clinician’s lameness assessment—
Grade 1 & 2 Elbow OA
Dogs given the label dose had a mean reduction in overall lameness score from baseline at each post-treatment interval—1, 3, 6, 9, and 12 months2
Reductions in mean clinician’s lameness assessment scores for dogs with Grade 3 elbow OA were seen at 3, 6, and 9 months2§
Force plate gait analysis—Grade 1 & 2 Elbow OA
82% of dogs showed significant increase in peak vertical force and/or mean vertical impulse after just 1 injection.2§
Measurements taken at 1, 3, 6, 9, and 12 months.
Treatment Success = an improvement in PF and/or IMP during follow-up visit compared to baseline. n=22 dogs
PF=peak vertical force;
IMP=mean vertical impulse
Canine brief pain inventory instrument—Grade 1 & 2 and Grade 3 Elbow OA2
In Grade 1& 2 OA, mean PSS and PIS scores showed statistically significant improvement at all time intervals compared to baseline2§
There was statistical agreement between clinician and pet owner assessments.2
§ Brown D. Canine Brief Pain Inventory User Guide, 2017. No measurements were taken at Month 1 for Grade 3 elbow OA dogs.
PSS=pain severity score;
PIS=pain interference score
§Results at label dose
Synovetin OA™ provides targeted, non-systemic therapy.1
Synovetin OA™ answers a significant unmet need.
References:
- Fox SM, Donecker JM. Synovitis. Technical Bulletin. Exubrion Therapeutics, July 2019.
- Data on File, Exubrion Therapeutics.
- Das BK. Role of radiosynovectomy in the treatment of rheumatoid arthritis and hemophilic arthropathies. Biomed Imaging Interv J. 2007;3(4):1-5. doi: 10.2349/biij.3.4.e45.
- Liepe K. 117mSn colloid in the radiosynovectomy. Presented at 2015 EANM, Hamburg, Germany, by Willem Uwe Kampen for the Bone and Joint Committee of EANM.
- Donecker JM, Stevenson NR. Radiosynoviorthesis: A new therapeutic and diagnostic tool for canine joint inflammation. Technical Bulletin. Exubrion Therapeutics, July 2019.